Online citations, reference lists, and bibliographies.
← Back to Search

Combination Of Raltitrexed And Oxaliplatin Is An Active Regimen In Malignant Mesothelioma: Results Of A Phase II Study.

K. Fizazi, H. Doubre, T. Le Chevalier, A. Rivière, Juliette Viala, C. Daniel, L. Robert, P. Barthélémy, A. Fandi, P. Ruffié
Published 2003 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
PURPOSE The aim of this open-label phase II study was to evaluate the activity of raltitrexed (Tomudex; AstraZeneca, Cergy, France) and oxaliplatin combination therapy in patients with diffuse malignant pleural mesothelioma. PATIENT AND METHODSs: Fifteen pretreated and 55 chemotherapy-naive patients (median age, 60 years; World Health Organization performance status of < or = 2) were enrolled. Most patients (66%) had advanced disease. Patients received raltitrexed 3 mg/m2 followed by oxaliplatin 130 mg/m2 every 3 weeks. RESULTS Twenty-four patients (34%) were classified as having a poor prognosis. In the overall study population, 14 patients (20%) had a partial response, and 32 patients (46%) had stable disease. The symptomatic response rates were as follows: shortness of breath, 36%; pain, 30%; activity, 23%; appetite, 21%; and asthenia, 20%. Median time to disease progression was 18 weeks (95% confidence interval [CI], 13 to 22 weeks). In chemotherapy-naive patients, median survival was 31 weeks (95% CI, 23 to 40 weeks) from the start of treatment and 49 weeks (95% CI, 40 to 52 weeks) from diagnosis of mesothelioma. In pretreated patients, median survival was 44 weeks (95% CI, 24 to 40 weeks) from the start of treatment and 226 weeks (95% CI, 63 to 292 weeks) from the diagnosis of mesothelioma. Overall 1-year survival was 26% (95% CI, 15.5% to 36.4%), survival was 22% (95% CI, 10.9% to 33.2%) in chemotherapy-naive patients and 40% (95% CI, 15.2% to 64.8%) in pretreated patients. Hematologic toxicity was mild, and there was no alopecia. The most common adverse events were asthenia, nausea/vomiting, and paraesthesia, and no treatment-related deaths were reported. CONCLUSION The raltitrexed and oxaliplatin combination is an active outpatient regimen in malignant mesothelioma and has an acceptable tolerability profile.
This paper references
Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer.
K. Fizazi (2000)
Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.
A. Alberts (1988)
The treatment of cancer pain.
K. Foley (1985)
Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma.
K. Fizazi (2000)
Diffuse malignant mesothelioma. Prospective evaluation of 69 patients.
A. Chahinian (1982)
A review of chemotherapy trials for malignant mesothelioma.
C. Ryan (1998)
933 Oxaliplatin (L-OHP®): Global safety in 682 patients (PTS)
S. Brienza (1995)
Chemotherapy for ovarian cancer.
S. Kaye (1993)
The emerging role of antifolates in the treatment of malignant pleural mesothelioma.
K. Fizazi (2002)
Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.
Y. Bécouarn (1998)
'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study Group.
D. Cunningham (1996)
New platinum complexes with anti-tumour activity.
T. Connors (1972)
Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients.
E. Chailleux (1988)
Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer.
P. Chollet (1996)
Continuing increase in mesothelioma mortality in Britain
J. Peto (1995)
The Treatment of Malignant Mesothelioma of the Pleura: Review of a 5‐Year Experience, With Special Reference to Radiotherapy
D. Ball (1990)
Rationale for development of platinum analogs.
J. Burchenal (1979)
Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines.
L. Kelland (1995)
Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.
P. Ruffié (1989)
The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.
V. Rusch (1991)
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
Chemotherapy in malignant pleural mesothelioma. A review.
S. T. Ong (1996)
Mature results from three large controlled studies with raltitrexed ('Tomudex').
D. Cunningham (1998)
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
A. de Gramont (2000)
Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma
W. Scheithauer (2001)
Occupational exposure to asbestos: population at risk and projected mortality--1980-2030.
W. Nicholson (1982)

This paper is referenced by
Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1).
C. Pinto (2006)
Traitement des pathologies tumorales du péritoine
D. Elias (2010)
4.2. Chimiothérapie du mésothéliome pleural malin
T. Berghmans (2006)
Targeting thymidylate synthase by antifolate drugs for the treatment of cancer
A. Jackman (2008)
Serie: Pleuraerkrankungen (6) Therapeutische Optionen beim malignen Pleuramesotheliom
M. Serke (2005)
Phase II Study of Gemcitabine Plus Docetaxel as Second-Line Treatment in Malignant Pleural Mesothelioma: A Single Institution Study
Ioannis S Tourkantonis (2011)
The Role of α-Folate Receptor-Mediated Transport in the Antitumor Activity of Antifolate Drugs
D. Theti (2004)
Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso
P. Hollen (2005)
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
C. Manegold (2005)
Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma.
H. Yano (2009)
Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid.
L. Krug (2006)
Advances in the Medical Treatment of Malignant Mesothelioma
K. Kuribayashi (2014)
Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.
P. Jänne (2008)
Emerging drugs for mesothelioma
G. Scagliotti (2007)
Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review.
B. Stordal (2007)
The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma: A Systematic Review and Practice Guideline
P. Ellis (2006)
The emerging role of antifolates in the treatment of malignant pleural mesothelioma.
K. Fizazi (2002)
Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program
P. Jänne (2006)
Quels résultats de l’immunothérapie dans les tumeurs thoraciques rares ?
N. Girard (2018)
Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma.
G. Utkan (2006)
Malignant pleural mesothelioma.
R. Hughes (2005)
First-Line Chemotherapy for Malignant Pleural Mesothelioma
P. Jänne (2005)
Chemotherapy for Malignant Pleural Mesothelioma
L. Garland (2011)
Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study.
M. Ralli (2009)
Analysis o f F actors A ssociated W ith O utcome i n P atients W ith Malignant P eritoneal M esothelioma U ndergoing S urgical Debulking a nd I ntraperitoneal C hemotherapy
A. Feldman (2003)
Second-line treatment for malignant pleural mesothelioma.
G. Ceresoli (2010)
Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin–proteasome pathway as a therapeutic target in poor prognosis tumors
A. Borczuk (2007)
Pemetrexed–cisplatin combination in mesothelioma
M. Reck (2005)
Second line therapy in malignant pleural mesothelioma: A systematic review.
W. Buikhuisen (2015)
An overview of chemotherapy for mesothelioma.
L. Krug (2005)
Second-Line Chemotherapy
N. Pavlakis (2005)
Pemetrexed and its emerging role in the treatment of thoracic malignancies
G. Scagliotti (2003)
See more
Semantic Scholar Logo Some data provided by SemanticScholar